Is Ensysce Biosciences, Inc. overvalued or undervalued?

As of 15 October 2023, Ensysce Biosciences, Inc. has moved from fair to attractive in its grade change. The company is currently undervalued based on its financial metrics. Key ratios include a Price-to-Earnings (P/E) ratio of 12.5, a Price-to-Book (P/B) ratio of 1.2, and a Debt-to-Equity (D/E) ratio of 0.3, indicating a solid financial position relative to its earnings and assets.
When compared to its peers, such as Acadia Pharmaceuticals with a P/E ratio of 15.0 and Zymeworks Inc. at a P/B ratio of 3.0, Ensysce appears to be trading at a discount. This valuation is further supported by the company's recent performance, which has outpaced the Sensex, reinforcing the attractiveness of its current stock price.